Amylyx Pharmaceuticals, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 1.33K shares, a 66500.00% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 465.66K shares, a 1182.46% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 80.14K shares, a 25.83% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 95.79K shares, a 160.30% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 213.09K shares, a 1.43% increase from fiscal 2024.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 210.09K shares, a 79.21% decline from fiscal 2023.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 1.01M shares, a 6.35% increase from fiscal 2022.
- Amylyx Pharmaceuticals, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 950.01K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 1.33K shares 10-Q · filed 2026-08-06 | 642.92K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 465.66K shares 10-Q · filed 2026-05-07 | 641.59K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | 80.14K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | 213.09K shares 10-K · filed 2026-03-03 |
| 2025-09-30 | 95.79K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 195.79K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | 2.00 shares 10-Q · filed 2026-08-06 | 136.80K shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | 36.31K shares 10-Q · filed 2025-05-08 | 196.78K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 63.69K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | 210.09K shares 10-K · filed 2025-03-04 |
| 2024-09-30 | 36.80K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | 333.95K shares derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | 59.98K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | 442.54K shares derived: sum of 4 quarters · filed 2024-08-08 |
| 2024-03-31 | 49.62K shares 10-Q · filed 2024-05-09 | 608.70K shares derived: sum of 4 quarters · filed 2024-05-09 |
| 2023-12-31 | 187.56K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | 1.01M shares 10-K · filed 2024-02-22 |
| 2023-09-30 | 145.38K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 1.10M shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 226.14K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 958.41K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 451.30K shares 10-Q · filed 2023-05-11 | 1.40M shares derived: sum of 4 quarters · filed 2023-05-11 |
| 2022-12-31 | 280.97K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-13 | 950.01K shares 10-K · filed 2023-03-13 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | |
| 2022-06-30 | 669.04K shares 10-Q · filed 2022-11-10 | |
| 2022-03-31 | 0.00 shares derived: 10-K 12 month − 3 quarters · filed 2023-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |